Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office									Atty. Docket No. A35478 066123.0125		al No. 687,402			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT								STA	TEMENT	Applicant Tyagi et al.				
(Use several sheets if necessary)						nece	ssar	y)	Filing Date October 16, 2003	Grou 165	•			
DEC 0	8 700	GEICE 39					,							
W.En.	TAGE								U.S. PATEN	T DOCUMENTS				
*Exam. Init.	Ala -				ument			,	Date	Name	Class	Subclass	Filing I	
St.	N	6	1	6	2	6	2	7	12/19/2000	Inouye et al.	435	194		-/
	L	<u></u>	1	<u>!</u>			L	FO	REIGN PA	L FENT DOCUMENT			J	
					ument				Date	Country	Class	SubClass	Transla Yes	
87	0	3	0	6	6	8	3	8	08/14/2003	WIPO				<u> </u>
## ## ## ## ## ## ## ## ## ## ## ## ##			And infer a m 85I - 7 Bail Struck Ball pos Ent Bar there Bar the Bar t	dersorderred in hycoly mitige 3 of M 8 ikalov ucture ltch, A stantible derocorrett, J rapy.	n D.H from t l tran , L.Y. fycobo , I., S of the iotic of ccus j .F. at Antin	., Hart wwo cu sferas , Jaga acteri chrod e Esc. Smith, effect faeciu nd Ho nicrol	th G., ystal e. J. Innatium tu er, I., so of L. R.P., so of L. C., J. C., Ago, Ago, R. R. a. a. R. a.	Hornstruc Mol. 1, C., hia co Ritz Y333 ntimi A. (1 R.A., nntimy	witz M.A. and tures of the Myc Biol. 307, 67 Wanger, A.R. adosis H37Rv: Exor – Grzeskowidi response regulation of the Myc Grob. Agents Corob.	and Norris, S.J. (2000) Disruptified on growth in culture and tak, M., Grzeskowiak, K., Gurallator NarL. Biochemistry 35, p., L.H. (1998) Comparison of tillin used singly and in combitation used singly and in combitation as 1529-1536 and Lee, R.E. (2000) Use of the proteins of Mycobacterium borroteins of Myc	facial mechanical major secretarion of gene ed in macrophage is alus, R.P. ar 11053 - 1106 finhibitory and ination against a target for magainst genomics and p, 221-231	sm and a clietory protein neoding ant ges. Infect. ad Dickerson l d bactericida vancomycinicrobial anti	igen 85A Immun. n, R.E. (al activiti n – resist in infecti	and 68, 76 1996) es and ant ve
NY02:505					,					1				· · · · · · · · · · · · · · · · · · ·
Examin	ier	m	_برک	J	~)	_		Date Cor	12-20-0	РС			

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•	è				
		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. A35478 066123.0125	Serial No. 10/687,402	
INI	FORMA	TION DISCLOSURE STATEMENT BY APPLICANT	Applicant Tyagi et al.		
	(Us	se several sheets if necessary)	Filing Date Group October 16, 2003 1651		
•		•	•		
H	 -	Bradford, M. M. (1976) A rapid and sensitive the principle of protein – dye binding. <i>Anal.</i>		icrogram quantities of protein utilizin	
1		Chen, P., Ruiz, R.E., Li, Q., Silver, R.F. and tuberculosis mutant lacking the alternate sign			
-		Cole et al. (1998) Deciphering the biology of Nature 393, 537 – 544	Mycobacterium tuberculosis from	the complete genome sequence.	
		Collins D.M., Kawakami R.P., de Lisle G.W., the principal sigma factor causes loss of virule Acad. Sci. USA 92, 8036 - 8040			
		Cooper J.B., McIntyre K., Badasso M.O., Wo analysis of the iron-dependent superoxide distreveals novel dimer-dimer interactions. J. Materials and the superoxide distribution of the super	mutase from Mycobacterium tuber		
•		Cox J.S., Chen B., McNeil M. and Jacobs W. Mycobacterium tuberculosis in mice, Nature		rmines tissue-specific replication of	
		Dasgupta, N., Kapur, V., Singh, K.K., Das, T. of a two-component system, devR-devS, of My			
		DeMaio J., Zhang Y., Ko C., Young D.B. and from Mycobacterium tuberculosis. Proc. Nat			
		Denis et al. (1999) Synthesis and antibacteria erthryomycin – resistant and susceptible patho			
		Deschenes, R.J., Lin, H., Ault, A.D. and Fass putative bacterial histidine kinase inhibitors.			
		Domagala, J.M., Alessi, D., Cummings, M., e in drug design: Inhibition of NRII by dipheno	•	0 0 . 0	
Doukhan, L., Predich, M., Nair, G., Dussurget, O., Mandic-Mulec, I., Cole, S.T., Smith, D.R. and Smith, I. Genomic organization of the mycobacterial sigma gene cluster. Gene 165, 67 - 70					

NY02:505269.1

2

Examiner A.

Date Considered

12-20-04

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		U.S. Department of Commerce tent and Trademark Office	Atty. Docket No. A35478 066123.0125	Serial No. 10/687,402	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Applicant Tyagi et al.		
	(Use	several sheets if necessary)	Filing Date October 16, 2003	Group 1651	
弄		Dziejman, M. and Mekalanos, J.J. (1995) two bacterial virulence factors in Hock, J.A. and S DC. American Society for Microbiology. Pp.	ilhavy, T.J. Eds. Two componer		
	 	El-Masry, A.H., Fahony, H.H. and Abdelwahe benzimidazole derivatives. <i>Molecules</i> 5, 1429		anti microbial activity of some new	
		Frechette, R.F., Beach, M.J., Bernstein, J. et a bacterial two-component signal transduction sy Meeting, Las Vegas, NV, USA			
		Glickman, M.S., Cox, J.S. and Jacobs, W.R. decoding, persistence and virulence of Mycobact			
		Grange, J.M. (1992) The mystery of the mycobacterial 'persistor'. Tuber. Lung Dis. 73, 249 - 251			
		Haydel, S.E., Dunlap, N.E. and Benjamin, W. phosphorylation between the <i>Mycobacterium t</i>			
		Himpens, S., Locht, C. and Supply, P. (2000) component system: evidence for autoregulation		e mycobacterial SenX3 – RegX3 two	
		Jackson, M., Crick, D.C. and Brennan, P.J. (2 J. Biol. Chem. 275, 30092 - 30099	2000) Phosphatidylinositol is an e	ssential phospholipid of mycobacter	
		Kinger, A.K. and Tyagi, J.S. (1993) Identification of Mycobacterium tuberculosis. Gene 131, 11		entially expressed in the virulent stra	
		Klimesova, V., Koc, J., Pour, M., Stachel, J., V evaluation of benzimidazole derivatives as anti			
		Klimesova, V., Koc, J., Waisser, K. and Kaussagents. Il Farmaco, 57, 259 – 265	tova, J. (2002b) New benzimidaz	zole derivatives as antimycobacterial	
/		Kramer, MJ and Grunberg, E. (1973) Effect o Chemotherapy, 19, 254 - 258	f ethidium bromide against transp	plantable tumors in mice and rats.	
l 2:505269.1	١.		3		

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	•				
		U.S. Department of Commerce stent and Trademark Office	Atty. Docket No. A35478 066123.0125	Serial No. 10/687,402	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Applicant Tyagi et al.		
	(Use	e several sheets if necessary)	Filing Date October 16, 2003	Group 1651	
•					
:JJ		Phetsuksiri, B., Baulard, A.R., Cooper, A.M., Antimycobacterial activities of isoxyl and new Antimicrob. Chemother. 43, 1042-1051			
1		Li, Z., Kelley, C., Collins, F., Rouse, D. and A associated with its growth and persistence in n			
		Macielag, M.J. and Goldschmidt, R. (2000) I Invest. Drugs 9, 2351 – 2369	inhibitors of bacterial two-compo	nent signalling system. Exp. Opin.	
		Manganelli, R., Voskuil, M.I., Schoolnik, G.K factor sigmaE: role in global gene expression			
		Matsushita, M. and Janda, K.D. (2002) Histochem. 10, 855 – 867	dine kinases as targets for new an	timicrobial agents. Bioor. Med.	
		Mayuri, Bagchi, G., Das, T.K. and Tyagi, J.S. Mycobacterium smegmatis. Expression analyst Rv3134c and chaperone – crystalline homolog	sis of the genes encoding DevR -	DevS two-component system,	
		McKinney, J.D., Bentrup, K.H., Munoz-Elias, Jacobs, W.R. Jr. and Russell, D.G (2000) P glyoxylate shunt enzyme isocitrate lyase. <i>Nat</i> .	ersistence of M. tuberculosis in n		
		Mitchison, D.A. (1998) How drug resistance of tuberculosis. Int. J. Tuberc. Lung Dis. 2, 10		iance during short – chemotherapy for	
		Mukamolova G.V., Kaprelyants A.S., Young Acad. Sci. USA. 95, 8916 - 8921	D.I., Young M. and Kell D.B. (1	998) A bacterial cytokine. Proc. Nat	
		Parkinson, J.S. and Kofoid, E.C. (1992) Com 26, 71 – 112	nmunication modules in bacterial	signalling proteins. Ann. Rev. Genet.	
		Parrish, N., Dick, J.D. and Bishai, W.R. (199 Microbiol. 6: 107 -112	8) Mechanisms of latency in Myc	obacterium tuberculosis. Trends	

NY02:505269.1

Examiner Land

Date Considered

Perez, E., Samper, S., Bordas, Y., Guilhot, C., Gicquel, B. and Martin, C. (2001) An essential role for phoP in

12-20-04

Mycobacterium tuberculosis virulence. Mol. Micro. 41, 179 - 87

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

à ·					
Form PT (REV. 2-		U.S. Department of Commerce atent and Trademark Office	Atty. Docket No. A35478 066123.0125	Serial No. 10/687,402	
INFO	RMAT	TION DISCLOSURE STATEMENT BY APPLICANT	Applicant Tyagi et al.		
	(Use	e several sheets if necessary)	Filing Date October 16, 2003	Group 1651	
· · //		Pohl, E., Holmes, R.K. and Hol, W.G. (1999 Mycobacterium tuberculosis shows both meta			
	·	Raman, S., Song, T., Puyang, X., Bardarov, S factor SigH regulates major components of ox <i>Bacteriol</i> . 183, 6119 - 6125			
		Ronning, D.R., Klabunde, T., Besra, G.S., Vis the secreted form of antigen 85C reveals poten 141 - 146			
		Roychoudhary, S., Zielinski, N.A., Ninfa, A.J (1993) Inhibitors of two-component signal tra Pseudomonas aerugin osa. Proc. Natl. Acad	nsduction systems: Inhibition of a		
, ,		Sherman, D.R., Voskuil, M., Schnappinger, D. Mycobacterium tuberculosis hypoxia response 7539			
•		Stead, W.W. (1967) Pathogenesis of a first er residuals of the primary infection or exogenous			
		Stead, W.W., Kerby, D.P., Schleuter, D.P. an adults. Confusion with reinfection in the path			
		Stephenson, K., Yamaguchi, Y., Hoch, J.A. (Signal transduction systems. J. Biol. Chem.		inhibitors of bacterial two-componen	
		Stock, A.M., Robinson, V.L. and. Goudreau, 69, 183 – 215	P.N. (2000) Two-component sign	nal transduction. Ann. Rev. Biochem	
		Stock, J.B., Surette, M.G., Levit, M. and Park function relationships and mechanisms of cata transduction. Washington, DC. American Sc	llysis. In: Hock, J.A. and Silhavy,	T.J. Eds. Two component signal	
		Stover, C.K., Warrener, P., VanDevanter, D.R. Towell, J.A., Yuan, Y., McMurray, D.N., Kre			

NY02:505269.1

Examiner

5

Strauch, M.A., De Mendoza, D. and Hoch, J.A. (1992) cis – Unsaturated fatty acids specifically inhibit a signal – transducing protein kinase required for initiation of sporulation in B. subtilis. Mol. Microbiol. 6, 2909 – 2917

In how

Date Considered

nitroimidaofuran drug candidate for treatment of tuberculosis. Nature 405, 962 - 66

12-20-04

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.	
A35478 066123.0125	10/687,402	
Applicant		
True of ot of		

Applicant Tyagi et al.	
Filing Date October 16, 2003	Group 1651

•,	
·St.	Ulijasz, A.T. and Weisblum, B. (1999) Dissecting the VanRS signal transduction pathway with specific inhibitors. J Bacteriol. 181, 627 – 631
	Upton, A., Johnson, N., Sandy, J. and Sim, E. (2001) Arylamine N-acetyltransferases - of mice, men and microorganisms. <i>Trends Pharmacol</i> . Sci. 22, 140 - 146
	Urbanski, M.J., Xiang, M.A., Foleno, B.D. et al. (1997) Novel cyclohexene derivatives with histidine protein kinase inhibitory activity - potential new antibacterial agents. Abstract No. 270, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, USA
	Wallis, N.G. (1999) Bacterial two-component signal transduction systems as drug targets. Curr. Opin. Anti-infect. Invest. Drugs. 1, 428 – 434
,	Weber, I., Fritz, C., Ruttkowski, S., Kreft, A. and Bange, FC. (2000) Anaerobic nitrate reductase (narGHJI) activit of Mybocaterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol. Microbiol. 35 1017 – 1025
•	West, M.L. and Fairlie, D.P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. <i>Trends Pharmacol.</i> Sci. 16, 67 - 94
	WHO report on the Global Tuberculosis Epidemic (1998) WHO Geneva
	Wilson T.M., de Lisle, G.W. and Collins, D.M. (1995) Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol. Microbiol. 15, 1009 - 1015
	Yuan, Y., Crane, D.C., Simpson, R.M., Zhu, Y.Q., Hickey, M.J., Sherman, D.R. and Barry, C.E. III. (1998) The 16 kDa a - crystalline (Acr) protein of <i>Mycobacterium tuberculosis</i> is required for growth in macrophages. <i>Proc. Natl. Acad. Sci.</i> USA 95, 9578 – 9583
	Zahrt, T.C. and Deretic, V., (2000) An essential two-component signal transduction system in Mycobacterium tuberculosis. J. Bacteriol. 182, 3832 – 3838
	Zahrt, T.C and Deretic, V. (2001) Mycobacterium tuberculosis signal transduction system required for persistent infection. Proc. Natl. Acad. Sci. (USA) 98, 12706 - 11
\bigvee	Zhang, Y. and Amzel, L.M. (2002) Tuberculosis drug targets. Current Drug Targets 3, 131 - 154
IY02:505269.1	. 6
Examiner /	Date Considered 12-20-04

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.